

### REMARKS


Upon entry of this amendment, claims 29-31 are pending in the instant application. In this response, claims 23-31 have been amended. The claims, as amended and added herein, are fully supported by the instant specification. Accordingly, no new matter has been added.

Examiner asserts that Applicants have not complied with the sequence election requirement as specified in Paper 16 mailed October 7, 2002. Examiner asserts that Applicants are required to elect a single nucleotide sequence such as SEQ ID NO:400. Applicants believe that this was done, but have amended the claims to more clearly elect a single sequence.

### CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicant  
c/o Mintz, Levin  
One Financial Center  
Boston, MA 02111  
Telephone (617) 542 6000  
Fax (617) 542 2241

Dated: February 27, 2003



*Version with Markings to Show Changes*

RECEIVED

MAR 04 2003

TECH CENTER 1600/2901

*In the Claims:*

Please amend the claims as follows:

29. An isolated polypeptide comprising a polymorphic site at one or more amino acid residues, wherein the protein is encoded by a [polynucleotide selected from the group consisting of] polymorphic nucleic acid sequence comprising SEQ ID NO:400, or its complement, [provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for said polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5] wherein the nucleotide corresponding to position 26 of SEQ ID NO:400 is not a guanosine.
30. The isolated polypeptide of claim 29, wherein said polypeptide is translated in the same open reading frame as is a wild type protein whose amino acid sequence is identical to the amino acid sequence of the polymorphic protein except at the site of the polymorphism.
31. The isolated polypeptide of claim 29, wherein the [polypeptide encoded by said] polymorphic sequence[, or its complement, includes the nucleotide listed in Table 1, column 6 for said polymorphic sequence, or the complement includes the complement of the nucleotide listed in Table 1, column 6] has an adenosine at position 26.